Motilal Oswal initiates coverage on Molbio Diagnostics stock with Buy, sees 21% upside. Here’s why
viaeconomictimes.indiatimes.com6 Oct
Motilal Oswal initiated coverage on Molbio Diagnostics with a Buy rating and ₹1,800 target, implying 21% upside. The brokerage sees strong growth potential from decentralised molec
Khabar Adda curates headlines like this across Top Stories, Entertainment, Bollywood, Hollywood, Crime and Politics from public RSS feeds. This page links out to economictimes.indiatimes.com's own reporting rather than reproducing it — the excerpt above comes from economictimes.indiatimes.com's own feed.
Read the full story on economictimes.indiatimes.com ↗